Quick Answer
Rani Therapeutics Holdings, Inc. reported Net Income of -$29.67 million for fiscal year 2025.
Rani Therapeutics Holdings, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$29.67M | +1.1% |
| 2024 | -$30.02M | +11.6% |
| 2023 | -$33.97M | -11.1% |
| 2022 | -$30.59M | -267.2% |
| 2021 | -$8.33M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.41M | +20.2% | +19.1% |
| June 30, 2025 | -$6.69M | +1.7% | +7.9% |
| March 31, 2025 | -$7.26M | +2.9% | -7.1% |
| September 30, 2024 | -$6.78M | +26.2% | +0.3% |
| June 30, 2024 | -$6.80M | +26.9% | +9.1% |
| March 31, 2024 | -$7.48M | +10.6% | +18.6% |
| September 30, 2023 | -$9.20M | -15.6% | +1.1% |
| June 30, 2023 | -$9.30M | -22.0% | -11.1% |
- Rani Therapeutics Holdings, Inc. showed an increase of +1.1% in Net Income compared to the prior fiscal year.
- Over the 2021–2025 period, Rani Therapeutics Holdings, Inc.’s net income has declined by 256.2% (from -$8.33 million to -$29.67 million).
- The most recent figure is from Rani Therapeutics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: